Brief: Aprea Therapeutics Announces Twice Daily (Bid) Dosing Of Patients In ABOYA-119 Clinical Trial Of ATRN-119 To Potentially Optimize Clinical Outcomes
11/12/2024 13:43
Dec 11 (Reuters) - Aprea Therapeutics APRE.O :
* APREA THERAPEUTICS ANNOUNCES TWICE DAILY (BID) DOSING OF
PATIENTS IN ABOYA-119 CLINICAL TRIAL OF ATRN-119 TO POTENTIALLY
OPTIMIZE CLINICAL OUTCOMES AND STRENGTHEN CLINICAL PATH FORWARD
* APREA THERAPEUTICS- DOSE ESCALATION IN ABOYA-119 TRIAL
EXPECTED
TO CONTINUE WITH BOTH ONCE-DAILY & TWICE-DAILY DOSING SCHEDULES
* APREA THERAPEUTICS INC -ANTICIPATES PHASE 1 READOUT IN
SECOND
HALF OF 2025
Source text: ID:nGNX5wfsFD
Further company coverage: APRE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aprea Therapeutics
See all newsAprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aprea Therapeutics Q2 net loss widens on higher R&D costs
Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
Brief: Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing